Anglo Asian Mining Share Discussion Threads

[bumpa33] 24/7/2024 08:53

Pogue - thanks for the POLB write up. The Irishman certainly seems to have the Midas touch…

[bumpa33] 24/7/2024 08:52

2cmb - I try my best.

[bumpa33] 24/7/2024 08:48

BZT - in at 0.024 - out at 0.032

[2cmb] 24/7/2024 08:48

LOL Bumpa' you certainly put a smile on my face with your comments.
Have a good day all. :-)

[bumpa33] 24/7/2024 08:37

some people are just far too easily impressed…

[jbravo2] 24/7/2024 08:16

Nicely done DP

[2cmb] 24/7/2024 08:01

DP'good luck for the future.

[katsy] 24/7/2024 07:50

Congratulation DP. Nice one.

[donald pond] 24/7/2024 07:45

"Thanks" bumpa!
And on the advisory board. But in all seriousness, I'm working very closely with the PXC team, particularly in Idaho, and looking forward to communicating much more than has been possible to date. I know you (and perhaps others) are sceptical. It is my job to prove you wrong. Let's judge me and the company on what the next few months and years reveal.

[bumpa33] 24/7/2024 07:27

…and still waiting for that funding news, don’t look like it’s coming today now 🤦🏻

[bumpa33] 24/7/2024 07:13

Wow. From “just” head of IR to Vice President. Well done Paul…! PXC

[sparkey_two] 24/7/2024 07:06

At what point does the board’s credibility start to drop. Changing to the word imminent suggested they had reassurance it was about to happen. Been a week and nothing.

How quickly can we restart if cost cutting has reduced resources to a minimum level, presumably people have left the area if no other work or secured other work.

[pogue] 23/7/2024 21:25

So POLB.
POLB is following a model successfully pioneered by a German company whose name I forget. Basically, get a pipeline of drugs and platforms for various ailments, they dont have to be connected, develop them to stage 2 ready then partner or sell them but keep royalties. The sales/partnering agreements generate immediate cash and the royalties over time provide a long term income. With the partnering its not expected they will put much money in if anything. The drugs for the pipeline have so far cost peanuts and the company is very well financed at around £12 million and even get given grants on occasion so plenty of cash to keep the pipeline rolling for a good time.
POLB’s first drug POLB001 has been out for sale for about a year. It prevents cytokine storms, basically when your body’s defence system over reacts to a threat it generates a condition that can kill you. This was what killed covid victims. Now you would have thought that would be an easy sell last year and indeed a pharma company was all over it for treatment of severe influenza but they never came up with a bid. So the team doing the work selling it were sacked and the team from Amryt were brought in. They focussed on its ability to assist new very strong cancer drugs work. Basically, there are new drugs out that work very well on cancer but have a high chance of producing a cytokine storm, one is as high as 80%. Whilst not always fatal the cancer victims have to be cared for and occupy hospital beds whilst recovering, if indeed they do. They have a rescue remedy which has some success but it only stops the cytokine storm after its has started, ie patients have to be hospitalised, whereas POLB0001 stops the stroms happening and is very good at that a lot more so than the rescue remedy I am led to beleive. So the cancer drug makers are very interested. The market for their drugs in £10 billion but is limited by how many beds victims occupy as no spare beds means they cannot use the drugs safely. So you can see the benefit of POLB001.
Currently 2 pharma companies have given POLB their cancer drugs so a test can be run using them. POLB001 is itself a repurposed drug and has been fully tested to be safe in humans for a few weeks which is all is needs for the cancer drugs. As for stopping cytokine storms it has also been proven. I assume the pharma companies want to test it with their drugs to make sure there is no interaction effect that inhibits it. I see that as a small chance. The drugs they received cost £millions we have been told so this trial will take place. I have been told they were aiming at year end. However apparently in these type of trials the contract for the trail actually contains an agreement on what will happen if the drugs prove successful ie a deal. Reason for this is the price of the drug will be a lot higher if its successful so a pharma company would want the deal signed before the trial, obviously if the trail fails the contract is void.
Sooo way I see it POLB have drug they know works going into a trial that it should pass easily and the contract should be appearing long before the end of the year so the trial can be set up and they already have the drugs to do the trial and the market for the drugs it will be sold with is £10 billion and without POLB001 they will be limited in how many they sell.
Worst case and somehow POLB001 fails there is a pipeline of drugs behind it and cash to move them up the trials chain so just got to wait for another. Have to be optimistic there though as it will half in value if this fails.
I await the trials RNS….
All very much my opinion, do your own research, this post is for entertainment not investing advice.
Don’t believe a word an anonymous poster posts on financial chat rooms.

[sideshowbull] 23/7/2024 21:10

Pogue the only bottom I can find is gap fill it's a little lower on my chart. ;-)

BWTFDIK

[pogue] 23/7/2024 20:54

SSB
I am not a holder of EEE, sold long time as I expected it to drift down no news I am waiting till the bottom to consider a punt as if what the CEO says is correct and he does seem to believe he has a world changing mineable platinum find then it should rocket. Keep an eye let me know when you reckon its found its bottom technically, would be grateful. The end of the year is when I expect news so time yet.

[bumpa33] 23/7/2024 20:43

Pogue - POLB info/post would be welcome I’m sure.

Ssb - no.

[thiopia] 23/7/2024 20:25

Mohamed El-Erian - 23/7/24

Why I am now optimistic that economies can break out of a rut

For the first time in two decades, I am optimistic that the economies of the advanced countries can decisively break out of a low-growth rut.

For too long, insufficient growth has undermined economic wellbeing, structurally weakened increasingly fragile public finances, worsened inequality and made it more difficult to address global threats to lives and livelihoods such as climate change and pandemics.

The roots of this problem can be traced back to the start of this century. Rather than focus on productivity-enhancing structural reforms, too many countries fell in love with financial services as a shortcut to growth. Some even acted as if finance provided the next stage of capitalist development — agriculture, industry, services and, now, finance.

It was a romance that saw regulators opt for “light touch�; approaches and countries compete fiercely to become international financial centres. There were few worries about the decoupling of an ever-expanding financial sector from the economies it was meant to serve — that is until it became unsustainable, culminating in the global financial crisis.

Rather than treating the crisis as evidence of structural failures, too many policymakers opted for a cyclical response — or the third T in the mantra then of “timely, targeted and temporaryâ€5533; policy approaches. In the absence of revamped engines of growth, fiscal deficits and the balance sheets of central banks expanded in magnitude more than anyone had imagined. Meanwhile, measures to strengthen productivity were, at best, piecemeal, inconsistent, and lacked a strategic framework.

After suffering the consequences, a rising number of governments are now placing growth at the top of the policy agenda. This is illustrated most vividly by the new UK government’s “growth missionâ€ʏ33; and its urgent implementation of measures to “release the brakesâ€ᦙ3;. A refreshed US administration is likely to follow suit.

This evolution is only part of the reason I am more optimistic about medium-term growth. The other is the realisation that releasing the brakes needs to be accompanied by the emergence of powerful new engines of tomorrowâ€T82;s growth; and there is enough scientific evidence to suggest that such engines are not just possible but also probable.

Seemingly every year, there are more impressive innovations in areas such as artificial intelligence, life sciences and sustainable energy. Each improves not just “what� we do but also “how� we do it. The trend is being spurred by abundant private sector financing, considerable human expertise and expanding computer power.

Together with these enablers, there are other sources of potential growth from the restructuring of specific sectors, creating beneficial “spillover� effects to the broader economy. This is the case for healthcare, food security and defence where there is significant scope for direct and indirect productivity gains.

This optimism is not without challenges. Each new growth driver comes with what I call 80/20 attributes — with the potential impact 80 per cent positive but also a 20 per cent possibility of negative consequences. The challenge is to unleash the promising benefits while managing the risk. In different countries, behavioural contexts will skew this. In the US, for example, innovators might tend to focus exclusively on the 80 per cent potential benefits. In Europe, regulators might be paralysed by the 20 per cent risk.

There is also the challenge of avoiding repeating the mistake with globalisation of losing sight of distributional consequences. The labour-augmenting potential rather than labour displacement risk of these innovations must be emphasised in an early and sustained manner. Visionary leadership will play an essential role here, as well as in navigating a fragmented world in which the potential for win-win co-operation has given way to divergence and fragmentation.

Yet the challenges, as real as they are, are not enough to curb my optimism. The potential for breakout growth is real and promising.

For years, I have worried that my generation was leaving our children a world of insufficient growth, terrible inequality, collapsing public services, high debt and a damaged planet. Today, I am more hopeful that they will have powerful new tools to overcome this awful legacy and enable their kids to live in a more prosperous, sustainable and equal world.

[sideshowbull] 23/7/2024 20:00

Bump Let me guess does it start with a P?


Pogue your EEE shat the bed.

Not sure I should comment on rest they may bully my BIRD.

Not advice.

BWTFDIK

SSB

[bumpa33] 23/7/2024 18:34

tomorrow a.m. we should see news on a fundraise. Might not be immediately apparent, but keep an eye on the ensuing TR1’s…

[doc60] 23/7/2024 16:27

No offence to any Irish on here but always thought Cathal Friel displayed a bit too much Irish blarney :)

[hubs] 23/7/2024 15:01

Cathal Friel now out of HVO. Long term, probably a positive as it seems a very steady ship with growth to come and in profit, niche market. He's past real usefulness for them. Short term...probably back to 27p for a while? We'll see, gla.